MedTrace Logo

S9005 Mifepristone in Meningioma

NCT03015701 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2019-12-23

No results posted yet for this study

Summary

To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma.

Conditions

  • Meningioma

Interventions

DRUG

Mifepristone

a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor

OTHER

Placebo

placebo matching mifepristone

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Charles Blanke, MD · Oregon Health and Sciences University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-08-31
Primary Completion
2001-10-31
Completion
2012-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015701 on ClinicalTrials.gov